Gregg Gilbert
Stock Analyst at Truist Securities
(2.29)
# 2,541
Out of 4,754 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $10.41 | +63.30% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $28.44 | +30.10% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $59.87 | +40.30% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $929.72 | -43.53% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $14.34 | -9.34% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $18.41 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $93.15 | -0.16% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $12.83 | +274.12% | 2 | Feb 2, 2021 | |
| CHRS Coherus BioSciences | Initiates: Buy | $26 | $1.01 | +2,487.06% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.55 | +27,172.73% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $29.00 | +168.97% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $170.53 | -54.26% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $16.00 | +12.50% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $112.18 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $140.22 | +24.80% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $211.48 | -68.79% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $10.41
Upside: +63.30%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $28.44
Upside: +30.10%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $59.87
Upside: +40.30%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $929.72
Upside: -43.53%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $14.34
Upside: -9.34%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $18.41
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $93.15
Upside: -0.16%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $12.83
Upside: +274.12%
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.01
Upside: +2,487.06%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.55
Upside: +27,172.73%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $29.00
Upside: +168.97%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $170.53
Upside: -54.26%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $16.00
Upside: +12.50%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $112.18
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $140.22
Upside: +24.80%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $211.48
Upside: -68.79%